Conformation and Supramolecular Structure of Lipid A

  • Klaus Brandenburg
  • Ulrich SeydelEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 667)


In recent years, lipid A as ‘endotoxic principle’ of bacterial lipopolysaccharide (LPS) and derivatives thereof have become increasingly important in the field of biomedical application such as for vaccination or as therapeutical, e. g., anti-tumor agent. For an understanding of these biological processes, however, a basic physicochemical characterization of lipid A and lipid A-like structures is a necessary prerequisite. This includes the determination of parameters like critical micellar concentration, the type of aggregate structure, the molecular conformation, the gel to liquid crystalline phase behaviour, and theoretical approaches like molecular modelling. In this chapter, data from literature are summarized showing that the unusual chemical structure of lipid A-type molecules is connected with a very complex structural polymorphism, which is sensitively dependent on the particular chemical primary structure, particular on the acylation pattern and on the number of phosphate groups at the diglucosamine backbone.


Acyl Chain Molecular Conformation Aggregate Structure Critical Aggregation Concentration Conical Conformation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rietschel ETh, Galanos C, Tanaka A et al. Biological activities of chemically modified endotoxins. Eur J Biochem 1971; 22:218–224.CrossRefPubMedGoogle Scholar
  2. 2.
    Rietschel ETh, Kirikae T, Schade FU et ale Bacterial endotoxin: Molecular relationships of structure to activity and function. FASEB J 1994; 8:217–225.PubMedGoogle Scholar
  3. 3.
    Nikaido H, Vaara M. Molecular basis of bacterial outer membrane permeability. Microbial Rev 1985; 49:1–32.Google Scholar
  4. 4.
    Golenbock DT, Hampton RW, Qureshi N et al. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 1991; 266: 19490–19498.PubMedGoogle Scholar
  5. 5.
    Mayer H, Krauss JH, Yokota A et al. Natural variants of lipid A. In: Friedman H, Klein TW, Nakano M and Nowotny A, eds Endotoxin, New York and London: Plenum press, 1990:45–70.Google Scholar
  6. 6.
    Loppnow H, Rietschel ETh, Brade H et al. Lipid A precursor Ia (compound 406) and Rhodobacter capsulatus lipopolysaccharide: Potent endotoxin antagonists in the human system in vitro. Levin, J, Alving, CR, Munford, RS et al. P. 337–348. 1993. Amsterdam, Elsevier. Bacterial endotoxin: Recognition and effector mechanisms.Google Scholar
  7. 7.
    Hofer M, Hampton RY, Raetz CRH et al. Aggregation behavior of lipid IVA in aqueous solutions at physiological pH. 1: Simple buffer solutions. Chem Phys Lipids 1991; 59:167–181.CrossRefPubMedGoogle Scholar
  8. 8.
    Takayama K, Din ZZ, Mukerjee P et al. Physicochemical properties of the lipopolysaccharide unit that activates B lymphocytes. J Biol Chem 1990; 265:14023–14029.PubMedGoogle Scholar
  9. 9.
    Buschner S. Bestimmung der kritischen Aggregatkonzentrationen von Lipiden: Implikationen fur die biologische Wirksamkeit von Endotoxinen. Universirat Kiel 1999; PhD Thesis.Google Scholar
  10. 10.
    Aurell CA, Wistrom AO. Critical aggregation concentrations of gram-negative bacteriallipopolysaccharides (LPS). Biochem Biophys Res Commun 1998; 253:119–123.CrossRefPubMedGoogle Scholar
  11. 11.
    Mueller M, Lindner B, Dedrick R et al. Endotoxin: Physical requirements for cell activation. J Endotoxin Res 2005; 11:299–303.PubMedGoogle Scholar
  12. 12.
    Mueller M, Lindner B, Kusumoto S et al. Aggregates are the biologically active units of endotoxin. J Biol Chem 2004; 279:26307–26313.CrossRefPubMedGoogle Scholar
  13. 13.
    Gioannini TL, Teghanemt A, Zhang D et al. Monomeric endotoxin: Protein complexes are essential for TLR4-dependent cell activation. J Endotoxin Res 2005; 11:117–123.PubMedGoogle Scholar
  14. 14.
    Takada H, Kotani S. Structural requirements of lipid A for endotoxicity and other biological activities. CRC Crit Rev Microbiol 1989; 16:477–523.CrossRefGoogle Scholar
  15. 15.
    Israelachvili JN. Electrostatic Forces Between Surfaces in Lipids. Intermolecular and Surface Forces, London: Academic Press, 1991: 213–259.Google Scholar
  16. 16.
    Luzzati V, Vargas R, Mariani P et al. Cubic phases of lipid-containing systems. Elements of a theory and biological connotations. J Mol Biol 1993; 229:540–551.CrossRefPubMedGoogle Scholar
  17. 17.
    Mariani P, Luzzati V, Delacroix H. Cubic phases of lipid-containing systems. Structure analysis and biological implications. J Mol Biol 1993; 204:165–189.CrossRefGoogle Scholar
  18. 18.
    Brandenburg K, Koch MHJ, Seydel U. Phase diagram of lipid A from Salmonella minnesota and Escherichia coli rough mutant lipopolysaccharide. I Struct Biol 1990; 105:11–21.CrossRefGoogle Scholar
  19. 19.
    Seydel U, Koch MHJ, Brandenburg K. Structural polymorphism of rough mutant lipopolysaccharides Rd to Ra from Salmonella minnesota. J Struct Biol 1993; 110:232–243.CrossRefPubMedGoogle Scholar
  20. 20.
    Brandenburg K, Richter W, Koch MHJ et al. Characterization of the nonlamellar cubic and HII structures of lipid A from Salmonella enterica serovar Minnesota by X-ray diffraction and freeze-fracture electron microscopy. Chem Phys Lipids 1998; 91:53–69.CrossRefPubMedGoogle Scholar
  21. 21.
    Brandenburg K, Mayer H, Koch MHJ et al. Influence of the supramolecular structure of free lipid A on its biological activity. Eur J Biochem 1993; 218:555–563.CrossRefPubMedGoogle Scholar
  22. 22.
    Schromm AB, Brandenburg K, Loppnow H et al. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur J Biochem 2000; 267:2008–2013.CrossRefPubMedGoogle Scholar
  23. 23.
    Seydel U, Schromm AB, Brade L et al. Physicochemical characterization of carboxymethyl lipid A derivatives in relation to biological activity. FEBS J 2005; 272:327–340.CrossRefPubMedGoogle Scholar
  24. 24.
    Brandenburg K, Lindner B, Schromm AB et al. Physico-chemical characteristics of triacyllipid A partial structure OM-174 in relation to biological activity. Eur J Biochem 2000; 267:3370–3377.CrossRefPubMedGoogle Scholar
  25. 25.
    Brandenburg K, Matsuura M, Heine H et al. Biophysical characterization of triacyl monosaccharide lipid A partial structures in relation to bioactivity. Biophys J 2002; 83:322–333.CrossRefPubMedGoogle Scholar
  26. 26.
    Brandenburg K, Andra J, Muller M et al. Physicochemical properties of bacterial glycopolymers in relation to bioactivity. Carbohydr Res 2003; 338:2477–2489.CrossRefPubMedGoogle Scholar
  27. 27.
    Seydel U, Oikawa M, Fukase K et al. Intrinsic conformation of lipid A is responsible for agonistic and antagonistic activity. Eur J Biochem 2000; 267:3032–3039.CrossRefPubMedGoogle Scholar
  28. 28.
    Jain MK. Nonrandom lateral organization in bilayers and biomembranes. In: Aloia RC Membrane Fluidity in Biology, Vol. I: Concepts of Membrane Structure, New York: Academic Press, 1983: 1–37.Google Scholar
  29. 29.
    Brandenburg K, Seydel U. Physical aspects of structure and function of membranes made from Iipopolysaccharides and free lipid A. Biochim Biophys Acta 1984; 775:225–238.CrossRefGoogle Scholar
  30. 30.
    Brandenburg K, Seydel U. Investigation into the fluidity of lipopolysaccharide and free lipid A membrane systems by Fourier-transform infrared spectroscopy and differential scanninig calorimetry. Eur J Biochem 1990; 191:229–236.CrossRefPubMedGoogle Scholar
  31. 31.
    Naumann D, Schultz C, Sabisch A et al. New insights into the phase behaviour of a complex anionic amphiphile: Architecture and dynamics of bacterial deep rough mutant lipopolysaccharide membranes as seen by FTIR, X-ray, and molecular modelling techniques. J Molec Struct 1989; 214:213–246.CrossRefGoogle Scholar
  32. 32.
    Naumann D, Schultz C, Born J et al. Investigations into the polymorphism of lipid A from lipopolysaccharides of Escherichia coli and Salmonella minnesota by Fourier-transform infrared spectroscopy. Eur J Biochem 1987; 164:159–169.CrossRefPubMedGoogle Scholar
  33. 33.
    Brandenburg K, Kusumoto S, Seydel U. Conformational studies of synthetic lipid A analogues and partial structures by infrared spectroscopy. Biochim Biophys Acta 1997; 1329:193–201.Google Scholar
  34. 34.
    Toman R, Garidel P, Andra J et al. Physicochemical characterization of the endotoxins from Coxiella burnetii strain Priscilla in relation to their bioactivities. BMC Biochem 2004; 5:1.CrossRefPubMedGoogle Scholar
  35. 35.
    Christ WJ, Asano O, Robidoux LC et al. ESS31, a pure endotoxin antagonist of high potency. Science 1995; 268:80–83.CrossRefPubMedGoogle Scholar
  36. 36.
    Bunnell E, Lynn M, Habet K et al. A lipid A analog, ESS31, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med 2000; 28:2713–2720.CrossRefPubMedGoogle Scholar
  37. 37.
    Mullarkey M, Rose JR, Bristol JU et al. Inhibition of endotoxin response by ESS64, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Therap 2003; 304: 1093–1102.CrossRefGoogle Scholar
  38. 38.
    Lynn M, Rossignol DP, Wheeler JL et al. Blocking of responses to endotoxin by ESS64 in healthy volunteers with experimental endotoxemia. J Infect Diseases 2003; 187:631–639.CrossRefGoogle Scholar
  39. 39.
    Asai Y, Iwamoto K, Watanabe S. The effect of the lipid A analog ESS31 on phospholipid membrane properties. FEBS Lett 1998; 438:15–20.CrossRefPubMedGoogle Scholar
  40. 40.
    Asai Y, Iwamoto K, Watanabe S. Characterization of the physicochemical properties of aggregates of the lipid A analog, ESS31, prepared by a ‘pH-jump method’. Chem Phys Lipids 1999; 97:93–104.CrossRefGoogle Scholar
  41. 41.
    Asai Y, Watanabe S. Effect of divalent cations on the membrane properties of the lipid. A analog ESS31. Drug Dev Ind Pharm 1999; 25:1107–1113.CrossRefPubMedGoogle Scholar
  42. 42.
    Gutsmann T, Schromm AB, Koch MHJ et al. Lipopolysaccharide-binding protein-mediated interaction of lipid A from different origin with phospholipid membranes. Phys Chem Chem Phys 2000; 2:4521–4528.CrossRefGoogle Scholar
  43. 43.
    Labischinski H, Barnickel G, Bradaczek H et al. High state of order of isolated bacterial Iipopolysaccharide and its possible contribution to the permeation barrier property of the outer membrane. J Bacteriol 1985; 162:9–20.PubMedGoogle Scholar
  44. 44.
    Frecer V, Ho B, Ding JL. Molecular dynamics study on lipid A from Escherichia coli: Insights into its mechanism of biological action. Biochim Biophys Acta 2000; 1466:87–104.CrossRefPubMedGoogle Scholar
  45. 45.
    Kato N, Naito S, Arakawa Y et al. Crystallization of synthetic Escherichia coli-type lipid A. Microbiol Immunol 1996; 40:33–38.PubMedGoogle Scholar
  46. 46.
    Brandenburg K, Wiese A. Endotoxins: Relationships between structure, function and activity. Curr Top Med Chem 2004; 4:1127–1146.CrossRefPubMedGoogle Scholar
  47. 47.
    Schromm AB, Brandenburg K, Loppnow H et al. The charge of endotoxin molecules influences their conformation and interleukin-6 inducing capacity. J Immunol 1998; 161:5464–5471.PubMedGoogle Scholar
  48. 48.
    Onier N, Hilpert S, Arnould L et al. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats. Clin Exp Metastasis 1999; 17:299–306.CrossRefPubMedGoogle Scholar
  49. 49.
    Reisser D, Pance A, Jeannin JF. Mechanisms of the antitumoral effect of lipid A. BioEssays 2002; 24:284–289.CrossRefPubMedGoogle Scholar
  50. 50.
    Pance A, Reisser D, Jeannin JE Antitumoral effects of lipid A: Preclinical and clinical studies. J Invest Med 2002; 50:173–178.CrossRefGoogle Scholar
  51. 51.
    Larmonier CB, Arnould L, Larmonier N et al. Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer. Int J Mol Med 2004; 13:355–361.PubMedGoogle Scholar
  52. 52.
    Seydel U, Labischinski H, Kastowsky M et al. Phase behaviour, supramolecular structure and molecular conformation of lipopolysaccharide. Immunobiol 1993; 187:191–211.Google Scholar
  53. 53.
    Wright SD, Ramos RA, Tobias PS er al. CDI4, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431–1433.CrossRefPubMedGoogle Scholar
  54. 54.
    Hoshino K, Takeuchi O, Kawai T et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol 1999; 162:3749–3752.PubMedGoogle Scholar
  55. 55.
    Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/He J and C57BL/I0ScCr mice: Mutations in Tlr4 gene. Science 1998; 282:2085–2088.CrossRefPubMedGoogle Scholar
  56. 56.
    Shimazu R, Akashi S, Ogata H et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189:1777–1782.CrossRefPubMedGoogle Scholar
  57. 57.
    Schromm AB, Lien E, Henneke P et al. Molecular genetic analysisof an endotoxin nonresponder mutant cell Line: A point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med 2001; 194:79–88.CrossRefPubMedGoogle Scholar
  58. 58.
    Blunck R, Scheel O, Müller M et al. New insights into endotoxin-induced activation of macrophages: Involvement of a K+ channel in transmembrane signaling. J Immunol 2001; 166:1009–1015.PubMedGoogle Scholar
  59. 59.
    Seydel U, Scheel O, Müller M et al. A K+channel is involved in LPS signaling. J Endotoxin Res 2001; 7:243–247.PubMedGoogle Scholar
  60. 60.
    Triantafilou M, Miyake K, Golenbock DT et al. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 2002; 1152:2603–2611.Google Scholar
  61. 61.
    Triantafilou K, Triantafilou M, Ladha S et al. Fluorescence recovery after photobleaching reveals that LPS rapidly transfers from CD14 to hsp70 and hsp90 on the cell membrane. J Cell Sci 2001; 114:2535–2545.PubMedGoogle Scholar
  62. 62.
    Mueller M, Brandenburg K, Dedrick R et al. Phospholipids inhibit lipopolysaccharide (LPS)-induced cell activation: A role for LPS-binding protein. J Immunol 2005; 174:1091–1096.PubMedGoogle Scholar
  63. 63.
    Schumann RR, Leong SR, Flaggs GW et al. Structure and function of lipopolysaccharidebinding protein. Science 1990; 249: 1429–1431.CrossRefPubMedGoogle Scholar
  64. 64.
    Hailman E, Lichenstein HS, Wurfel MM et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CDI4. J Exp Med 1994; 179:269–277.CrossRefPubMedGoogle Scholar
  65. 65.
    Gutsmann T, Haberer N, Carroll SF et al. Interaction between lipopolysaccharide (LPS), LPS-binding protein (LBP) and planar membranes. Biol Chem 2001; 382:425–434.CrossRefPubMedGoogle Scholar
  66. 66.
    Gutsmann T, Mueller M, Carroll SF et al. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 2001; 69:6942–6950.CrossRefPubMedGoogle Scholar
  67. 67.
    Roes S, Mumm F, Seydel U et al. Localization of the lipopolysaccharide-binding protein in phospholipid membranes by atomic force microscopy. J Biol Chem 2006; 281:2757–2763.CrossRefPubMedGoogle Scholar
  68. 68.
    Gioannini TL, Teghanemt A, Zhang D et al. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA. 2004; 101:4186–4191.CrossRefPubMedGoogle Scholar
  69. 69.
    Takayama K, Mitchell DH, Din ZZ et al. Monomeric Re lipopolysaccharide from Escherichia coli is more active than the aggregated form in the Limulus amebocyte lysate assay and in inducing Egr-1 mRNA in murine peritoneal macrophages. J Biol Chem 1994; 269:2241–2244.PubMedGoogle Scholar
  70. 70.
    Shnyra A, Hultenby K, Lindberg AA. Role of the physical state of Salmonella lipopolysaccharide in expression of biological and endotoxic properties. Infect Immun 1993; 61:5351–5360.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  1. 1.Division of Biophysics Research Center BorstelLeibniz-Center for Medicine and BiosciencesBorstelGermany

Personalised recommendations